Vivid Vision Perimetry. Digital endpoints for GA, AMD, and Glaucoma clinical trials.

get 6.8x more precision using

TARGETED MICROPERIMETRY

for

Retina & Glaucoma

in your next trial

Vivid Vision Perimetry, high precision home visual field testing for clinical trials.

&

introducing

VIVID VISION PERIMETRY

...offering

AFFORDABLE, MOBILE

automated perimetry!

Slide background

Vivid Vision is also an advanced vison training system for

AMBLYOPIA, STRABISMUS, & CI

Discover a world
with depth perception!

3D VISION

by training your

DIGITAL
ENDPOINTS

VVP is being used as a targeted microperimetry endpoint in clinical trials for GA, AMD, and glaucoma.

PARTNER WITH US

VISUAL
FIELD

Learn more about how Vivid Vision Perimetry is used to measure visual fields.

LEARN ABOUT VVP

VT FOR
PATIENTS

Find a Vivid Vision Provider
who can provide vision training.

FIND A PROVIDER

EYEBAB
VT

To take your patients to the next level, EYEBAB offers a suite of dozens of vision activities.

DISCOVER EYEBAB VT

Pioneering digital solutions for vision care

Used by more than 100,000 patients, in 50+ countries, since 2014.

Proven Superior to In-Clinic Microperimetry

Groundbreaking study shows that at-home natural fixation VR-based vision testing matches the accuracy of in-clinic microperimetry while providing greater precision.

See the Study Results
6.8x
More Precision Than SAP
2x
Better Fixation Stability
99%
Adherence to at-home testing
Research by Leading Experts
Study sponsored by Regeneron and conducted by Dr. Karl Csaky at the Retina Foundation of the Southwest, a premier research institution.
Industry Partnerships
Used by the largest ophthalmic pharma companies, demonstrating industry confidence in Vivid Vision Perimetry as a functional vision endpoint for clinical trials.
Clinical Trial Ready
Targeted microperimetry is already validated for use as an endpoint in phase I and II clinical trials for geographic atrophy, AMD, and glaucoma therapeutics.

What Leading Researchers Are Saying

"

Vivid Vision's visual field test is extremely promising to use as an endpoint in clinical trials. I am personally excited about the potential it has for helping pharmaceutical companies bring their new therapeutics to market.

- Eleonora Lad, MD, PhD
Vice Chair of Clinical Research, Ophthalmology
Duke University Medical Center
"

At the RFSW, we were proud to be the first site to evaluate VVP tests in patients with Geographic Atrophy. For our GA patients, VVP wasn't just a novel tool, it became the test of choice.

- Karl Csaky, MD, PhD
CEO, CMO
Retina Foundation of the Southwest
Use VVP in your next clinical trial

We are committed to quality

Our system goes through scientific testing and rigorous quality management procedures

OUR PUBLICATIONS